Remimazolam is a benzodiazepine derivative drug as an alternative to the short-acting imidazobenzodiazepine midazolam, for use in induction of anaesthesia and conscious sedation for minor invasive procedures.?Remimazolam was found to be both faster acting and shorter lasting than midazolam, and human clinical trials showed a faster recovery time and predictable, consistent pharmacokinetics, suggesting some advantages over existing drugs for these applications.?

VIP (10-28) (human, bovine, porcine, rat)

NCGC00378430 is a potent?SIX1/EYA2?interaction inhibitor that disrupts the SIX1/EYA2 complex, EMT, and Metastasis.